Overview


According to FutureWise analysis the market for lupus therapeutics in 2023 is US$ 2.94 billion, and is expected to reach US$ 5.78 billion by 2031 at a CAGR of 8.82%.

An autoimmune disorder called lupus causes the body's immune system to attack its own healthy tissues and organs, causing swelling, tissue damage, and agony. The joints, kidneys, brain, blood cells, skin, heart, and lungs can all experience lupus-related inflammation. Although there is no known cause for lupus, there are several risk factors that are connected to the disease. These risk factors include heredity, smoking, hormones, viral infection, and others. Fatigue, joint and muscle discomfort, fever, mouth sores, headaches, arthritis, malar rash, odd hair loss, and others are some of the symptoms of lupus that are frequently seen. Lupus is challenging to diagnose since its symptoms resemble those of rheumatoid arthritis, scleroderma, and other conditions. A very recognisable sign of lupus, however, is a butterfly-shaped rash over the cheek and nose known as a malar rash. Urinary tract infections, yeast infections, herpes, pregnancy loss, bone tissue death, and other issues can also result from lupus. The major factors that are anticipated to propel growth of the global lupus therapeutic market over the forecast period include the high prevalence and incidence of lupus, rapid research and development activities toward development of novel therapeutics for treatment of lupus, and increasing adoption of inorganic growth strategies, such as acquisitions and collaborations, by key players operating in the market. One of the key reasons impacting the growth of the global market for lupus treatments is the increasing prevalence of lupus illnesses worldwide. In addition, it is anticipated that increasing investments in high-end, technologically advanced healthcare infrastructure and facilities in both developed and developing nations would promote the growth and development of the global market for lupus therapies in the years to come.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Lupus Therapeutics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Lupus Therapeutics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Hikma Pharmaceuticals Plc
  • Dr. Reddy’s Laboratories Ltd.
  • GlaxoSmithKline
  • Novartis AG
  • Sanofi
  • ImmuPharma
  • Bayer
  • Aurinia Pharmaceuticals
  • Pfizer Inc.
  • Astra Zeneca
  • MedImmune
  • F.Hoffmann-La Roche
  • Bristol Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • BoehringerIngelheim International Gmbh

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Acute Cutaneous Lupus
  • Chronic cutaneous lupus erythematosus, or discoid lupus erythematosus (DLE)
  • Subacute cutaneous lupus erythematosus

By Drug Classes

  • Immunosuppressants
  • Corticosteroids
  • NSAIDs
  • Antimalarials
  • Biologics

By Route of Administration

  • Subcutaneous
  • Oral
  • Intravenous

By Distribution Channel

  • Hospital Pharmacies
  • Retail/ Drug Stores
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa


  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Lupus Therapeutics Market By Type, By Drug Classes, By Route of Administration, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Lupus Therapeutics Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Lupus Therapeutics Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Lupus Therapeutics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Lupus Therapeutics Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Acute Cutaneous Lupus
        2. Chronic cutaneous lupus erythematosus, or discoid lupus erythematosus (DLE)
        3. Subacute cutaneous lupus erythematosus

  • 8.   Lupus Therapeutics Market, By Drug Classes Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Immunosuppressants
        2. Corticosteroids
        3. NSAIDs
        4. Antimalarials
        5. Biologics

  • 9.   Lupus Therapeutics Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Subcutaneous
        2. Oral
        3. Intravenous

  • 10.   Lupus Therapeutics Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail/ Drug Stores
        3. Online Pharmacies

  • 11.   North America Lupus Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Lupus Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Lupus Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Lupus Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Hikma Pharmaceuticals Plc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Dr. Reddy’s Laboratories Ltd.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. GlaxoSmithKline
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Novartis AG
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Sanofi
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. ImmuPharma
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bayer
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Aurinia Pharmaceuticals
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Pfizer Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Astra Zeneca
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. MedImmune
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. F.Hoffmann-La Roche
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Bristol Myers Squibb Company
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Teva Pharmaceutical Industries Ltd.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. BoehringerIngelheim International Gmbh
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients